Release – The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

Posted on August 18, 2026August 18, 2026 by [email protected]

Shelton, Connecticut – Tuesday, August 18, 2026.

NanoViricides, Inc. (NYSE American: NNVC) (the “Company”), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses is expected to begin soon in the Democratic Republic of Congo (“DRC”).

Professor Patrick Katoto has been appointed as the principal investigator to lead this clinical trial. Dr. Katoto 1 is Co-Director and Co-Founder of the Centre for Tropical Diseases and Global Health (“CTDGH”), and Associate Professor of Medicine, Epidemiology and Global Health at the Catholic University of Bukavu, Bukavu, DRC. He has more than ten years of working experience as a clinician, academic, and advisor for multiple public and private health agencies. He works on various projects of global health concern to produce evidence to inform decision-making to address Ebola, COVID-19, HIV, tuberculosis, vaccine-preventable diseases, non-communicable diseases, as well as air pollution in resource-limited settings. He has published over fifty papers in renowned journals such as Lancet and JACC. He has co-authored a paper entitled “How to prepare for the next inevitable Ebola outbreak: lessons from West Africa [2014-2016]” in 2024 in Nature Medicine 2.

Patrick is a Fogarty Fellow (HIV-comorbidity research training program in Low and Medium Income Countries (“LMIC”s), a Fellow of the Central & West Africa Implementation Science Alliance for the establishment of a network in implementation research (known as “CAWISA”, in collaboration with the University of Maryland Baltimore, Institute of Human Virology Nigeria, Yale University and other organizations) to accelerate the scaling up of novel diagnostic tools and clinical guidelines to improve children’s health, a fellow of the Pan-African Scientific Research Council and a member of the Institute for Health Metrics’ Global Burden of Diseases project (University of Washington).

Under the leadership of Professor Katoto, NanoViricides, as the drug sponsor of NV-387 Oral Gummies, has received regulatory approval to begin a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus and other Ebola viruses, from the local regulatory agency ACOREP in the Democratic Republic of Congo (DRC).

Professor Katoto and his team have already actively started the preparatory work including staff training, to accelerate time to first patient dosing, even without waiting for the regulatory approval. This has a given a head start to our efforts.

Additionally, the drug product for the clinical trial is already available in DRC, because of the impending Phase II clinical trial of NV-387 Oral Gummies as a Treatment for Mpox.

Therefore, it is anticipated that the first Ebola patient dosing with NV-387 oral gummies under this clinical trial can be expected to occur within a few weeks, barring impediments caused by the very ebola disease outbreak that the trial is designed to respond to.

“We now eagerly await the first dosing of Ebola patients with our NV-387 Oral Gummies drug product that is already in place in DRC,” said Anil R. Diwan, PhD, President of the Company, adding, “We, our colleagues, and our partners are hoping that this orally available, unique and revolutionary broad-spectrum antiviral drug succeeds in combatting the Bundibugyo virus for which there is no known treatment or vaccine.”

1 https://ctdgh.org/researchers/prof-dr-katoto-pdm , also see-https://cawisa-afr.org/team-member/patrick-dmc-katoto/

2 http://europepmc.org/abstract/med/39420216
As the Ebola outbreak continues to expand, several limitations on travel are being instated. There are also limitations on availability of resources such as PPE and diagnostic kits, which are compounded by the travel and other restrictions. These on-ground situations have caused delays in our efforts, and we anticipate such delays to continue due to the tenuous outbreak situation.

The current Ebola Virus Disease (EVD) caused by the Bundibogyo ebolavirus (BDBV) is now the largest ever ebola outbreak, as well as the fastest growing ebola outbreak in DRC. As of August 14, 2026, there have been 4945 confirmed cases, and 2325 deaths, with 101 new cases being confirmed in the previous 24 hrs 3. In comparison, as of August 6, 2026, there were reported 4,141 confirmed cases and 1,889 confirmed deaths due to this virus. Only 829 confirmed cases were then reported to have recovered from the disease. The crude fatality rate (crude CFR) is 46%, according to the WHO 4.

This is an increase of 20% in cases as well as deaths over the prior week. At this rate, the current deadly outbreak is on track to exceed the worst ever ebola zaire outbreak in West Africa in 2014-2016. In that outbreak, 28,616 cases and 11,310 deaths were recorded across Guinea, Liberia and Sierra Leone, according to the World Health Organization (ibid, #3).

An oral drug to treat patients, to prevent contacts from contracting the disease, and to keep healthcare workers safe, is sorely needed to combat this outbreak. There is a tremendous urgency to validate a drug that works against this ebolavirus in short and decisive clinical trials for minimizing further spread by treating patients and for saving lives. Om Sai CRO, in consultation with renowned scientists in DRC, has designed the Phase II clinical trial with this particular objective.

In contrast, the “PARTNERS” clinical trial (see below) will require over 1,000 patients to be treated and may not yield results for at least more than a year. A similar large collaborative clinical trial effort in the West Africa 2014-2016 outbreak resulted in US FDA approval of two antibody drugs only specifically for EBOV Zaire, which are not deemed to be useful in the current outbreak without further clinical trials.

NV-387 is the only orally active agent under consideration for clinical trial as a treatment of Ebola to the best of our knowledge. In an epidemic scenario in resource limited settings such as in DRC, we believe an oral drug is a highly advantageous feature.

An oral drug called obeldesivir, which is related to the known drug remdesivir that previously failed in clinical trials against Ebola Zaire, is being tried in a clinical trial, but only as a preventative measure, and not as a treatment of active infection.

NanoViricides has retained Om Sai Clinical Research Private Limited, India, (Om Sai CRO) as the CRO for this Phase II clinical trial for Ebola in DRC. Om Sai CRO has been instrumental in putting together the team with Prof. Katoto and other renowned experts and with support from the University ofukavu and in the Ebola-affected region to lead and execute the clinical trial of NV-387 Oral Gummies as a Treatment for Ebola viruses in DRC.

This Ebola outbreak continues to increase in spread and is now present in at least six provinces in

3 https://www.cbc.ca/news/world/drc-ebola-outbreak-deadliest-in-history-9.7309296

4 https://www.who.int/emergencies/alert-and-response . The crude CFR is estimated as number of

deaths (1,889) divided by number of reported confirmed cases (4,141) since May 16, the declaration of the epidemic. Most of the remaining 1,423 cases are likely to be continuing as disease-stricken. The crude CFR does not take into account the delay period between case confirmation to case fatality (i.e. the disease duration), and results in an underestimate of the case fatality rate while the epidemic is still increasing, as is the case at present in DRC.

The largest ever Ebola outbreak was the West Africa Ebolavirus (Zaire) outbreak, in 2013-2016, that killed more than 11,000 people out of at least 28,000 cases. The current outbreak, caused by a different, rare Bundibugyo strain of the ebolavirus, has already surpassed that outbreak in becoming the fastest growing Ebola outbreak to date, according to the WHO.

DRC and threatening South Sudan 5. More concerning is the fact that over 80% of new cases are outside of known contact lists, leading to the projection that the extent of the outbreak is at least two times or more larger than the reported confirmed cases 6. Additionally, Ebola is now found to have spread into displacement camps that host over 4.4 million displaced persons due to internal warfare, adding another high risk population pool with poor drinking water, sanitation and medical resources to further fuel this outbreak, according to the UN New Service 7.

Treatments under consideration except for NV-387 which is orally available, require infusions. Infusions are difficult to implement and also are not scalable in a large outbreak scenario such as this Ebola virus outbreak if it continues to grow, as has been widely expected.

A clinical trial, called the “PARTNERS” clinical trial, evaluating Remdesivir infusion, an antibody cocktail MBP134 infusion, and MBP134 infusion plus Remdesivir infusion, has started according to WHO with first patient having received infusion of the antibody cocktail on July 2, 2026 8.

“Although this antiviral (Remdesivir) proved to be ineffective at targeting the Zaire Ebolavirus, there remains hope that it could have some benefit against the Bundibugyo virus, particularly if used in combination with MBP-134,” according to an article in Forbes explaining the “PARTNERS” clinical trial

by the WHO organized collaboration 9. The article also notes that MBP134 contains two separate

antibodies designed to, taken together, recognize multiple Ebola species.

Antibodies are highly specific to a particular strain of the virus and usually are not very effective against variants of the same virus that arise in the field. Viruses also escape antibodies readily by mutations in the field.

The Company notes that NV-387 was previously found to be superior to Remdesivir in a lethal animal model of a viral disease. The Company believes this superiority of NV-387 is reasonably expected to extend to the current novel Bundibugyo ebolavirus strain.

There is no approved Treatment or Vaccine for the new variant of the Bundibugyo Ebolavirus (BDBV) that is causing the current rapidly expanding outbreak of the Ebolavirus Disease (EVD) in DRC. The rare Bundibugyo strain of Ebola virus causing the current outbreak appears to be its new variant, likely freshly introduced from some animal source 10, such as fruit bats.

A new clinical trial of an Oxford University designed Bundibugyo-specific vaccine has also started in DRC, in addition to the treatment trials of antibody and remdesivir infusions (ibid, #8). Further, Ervebo, a vaccine approved for Ebolavirus Zaire, may also enter clinical trials for the protection of uninfected persons from the distinctly different Bundibugyo ebolavirus due to the enormity of the

5 https://www.aljazeera.com/news/2026/7/20/ebola-death-toll-in-drc-surges-to-at-least-930-as-outbreak-gathers-pace

https://www.aljazeera.com/news/2026/7/16/ebola-spreading-more-quickly-in-drc-while-uganda-is-close-to-being-virus-free

6 https://www.msn.com/en-us/health/other/congos-ebola-outbreak-spreads-to-two-more-provinces/ar-AA27NkjT

7 https://www.msn.com/en-xl/africa/top-stories/ebola-virus-reaches-displacement-camps-in-dr-congo/ar-AA29A5ts?ocid=BingNewsSerp

8 https://www.reuters.com/business/healthcare-pharmaceuticals/trial-bundibugyo-ebola-treatment-starts-drc-who-says-2026-07-02/

9 https://www.forbes.com/sites/omerawan/2026/07/07/new-clinical-trials-offer-hope-in-the-fight-against-ebola-in-the-democratic-republic-of-congo/

10 https://virological.org/t/initial-genomes-from-may-2026-bundibugyo-virus-disease-outbreak-in-the-democratic-republic-of-the-congo-and-uganda/1032

emergency posed by the current outbreak despite reservations regarding a potentially imperfect vaccine 11. Om Sai is the CRO leading the Company’s Phase II clinical trial of NV-387 Oral Gummies as a

Treatment for Mpox in DRC, and the same CRO is also leading the newly approved Ebola clinical trial.

Sufficient quantity of NV-387 Oral Gummies Drug Product for starting the clinical trial against Ebola is already available in DRC. This drug product was shipped to DRC for the ensuing Phase II clinical trial of NV-387 for the Treatment of Mpox and also to support the Phase II clinical trial for the Treatment of Ebola only upon approval by the regulatory agency, which has now been approved.

“We believe NV-387 could be revolutionary in this fight against Ebola, if it is found to be effective,” said Anil R. Diwan, PhD, adding, “It is an oral drug, in contrast to others that are infusions. Thus evaluating if NV-387 treatment works is of paramount importance to combat this and future Ebola and Marburg outbreaks.”

NV-387 is a broad-spectrum antiviral that mimics the host-side features that the virus requires, and is likely to be effective against Ebola viruses because they use the same host-side feature mimicked by NV-387.

It is highly unlikely that viruses can escape NV-387, because this drug mimics the features on host cells that the viruses continue to require even as they mutate or evolve in the field.

Additionally, NV-387 Oral Gummies is a drug product readily delivered orally. It does not even require swallowing effort or water, because it dissolves in the mouth by itself, simplifying delivery for even sick individuals with swallowing difficulties.

This oral delivery is an important feature that puts NV-387, a broad-spectrum antiviral, as being superior to the other approaches.

“Only safe and effective broad-spectrum antiviral drugs like NV-387 that can effectively tackle most viral infections will enable the world to combat viruses and defend the global population in the war against known and unknown nanoscopic enemies that are viruses,” commented Dr. Diwan, adding, “Today, NV-387 is the only drug in clinical development with such broad-spectrum potential that promises to combat diverse epidemics like Mpox and Ebola, to the best of our knowledge.”

While there is currently minimal risk of Ebola in the USA, the CDC’s mathematical models suggested this Central African outbreak could grow to 10,000 to 20,000 cases and 2,000 to 4,000 deaths within just three months, rivaling the largest outbreak to date in 2014-2016 12. Unfortunately, the outbreak appears to be even more aggressive than the CDC model, with over 2,000 deaths in less than three months, over 4,000 confirmed cases, and over 10,000 estimated total cases 13.

The outbreak which was declared a Public Health Emergency of International Concern (“PHEIC”) by the WHO on May 17, 2026, continues to rapidly expand, outpacing containment efforts. The outbreak arose in a high traffic region bordering the Democratic Republic of Congo (DRC), with travel contacts to Uganda, and South Sudan and with 11 more nations in Africa at risk 14.

NV-387 is a broad-spectrum antiviral that mimics the host-side feature called heparan sulfate

11 https://www.msn.com/en-us/health/general/ebola-cases-top-4-000-in-drc-as-who-urges-ervebo-vaccine-trial/ar-AA29CX9f?ocid=BingNewsSerp .

12 https://www.cdc.gov/media/releases/2026/update-on-ebola-outbreak-in-the-democratic-republic-of-the-congo-and-uganda-6-5-2026.html

13 The WHO and Africa CDC have estimated that the confirmed case number substantially under-represents actual case numbers which could be at least double or even more than confirmed cases. See #5.

14 https://www.forbes.com/sites/maryroeloffs/2026/05/25/african-health-officials-on-ebola-this-is-too-much-live-updates/

proteoglycan (HSPG) that over 90-95% of human pathogenic viruses require for infecting cells. No matter how much the virus changes in the field, it continues to use HSPG, and therefore it cannot escape the drug NV-387. In contrast, Remdesivir is a small molecule inhibitor of the viral RDRP enzyme needed for making copies of the viral genome, and the virus can possibly escape by small number of mutations.

All Ebola viruses utilize HSPG as the attachment receptor prior to gaining entry into the cell. Thereafter, followed by entry into the cell inside endosomes, the ebolavirus surface glycoprotein is substantially degraded, opening up its site for binding to its cognate receptor called NPC1, thereby entering into the cytoplasm where the next steps in its replication begin.

Thus there is a strong rationale that NV-387 could be highly effective against Ebola virus infections, not just Bundibugyo, but also the Sudan and other viruses for which there are no treatments.

NV-387 is available as an oral medication that has excellent stability at room temperature, enabling ease of transport, distribution, and delivery to patient. NV-387 oral gummies dissolve naturally in the mouth and do not require tablet swallowing, which is difficult for children, seniors, and also patients with sore throat.

All previous anti-Ebola efforts have been focused on vaccines and antibodies 15. This has led to approval of therapies that are specific to the Ebolavirus Zaire strain only, albeit with limited effectiveness. This leaves out all other filoviruses of consequence: Sudan, Marburg, and the more rare Bundibugyo with no treatment or vaccine.

In contrast, if NV-387, as a broad-spectrum antiviral, is found to be effective against the Bundibugyo virus, it will likely be effective against all ebolaviruses and possibly all filoviruses; that would be a game changer for pandemic preparedness.

The case fatality rate of ebolaviruses has generally been approximately 50% in recent outbreaks, with improvements in care, including hydration therapy, corticosteroids, and other usual symptomatic treatments. Ebola viruses spread via bodily fluid secretions including fomites/sputum, as well as semen/ genital secretions. Ebola virus can remain in survivors even as many as 965 days after the disease without symptoms, and can transmit through bodily secretions, suggesting possible latency. Many recent outbreaks have been ignited as a result of such reawakened-transmitted virus from a survivor. Sexual transmission was documented even as late as 482 days after disease. This persistence and possible latency of ebolavirus in immune-privileged organs (e.g. brain, eyes, gonads, where antibodies are not operative) makes it a uniquely serious threat for global transmission and sustained outbreaks.

At present, BDBV has been consistently demonstrating crude CFR exceeding 46% in DRC. Therefore, BDBV is of great concern as a potential pandemic disease. However, it is believed that ebolaviruses do not transmit via respiratory droplets or aerosols and rather require extensive contact with bodily fluids of an infected person. In addition, within DRC and internationally, certain protective quarantine measures for travel from the outbreak areas have been implemented.

Therefore, currently there is no apparent threat of a global pandemic.

An irony is that because of the high case fatality rate (CFR) approaching 50%, the spread of ebolaviruses remains rather limited. If a variant emerges with a reduced CFR, say in the range of 5-15%, the potential threat of global pandemic from such an outbreak would increase substantially.

With ever-increasing global travel, local outbreaks such as ebola can quickly travel far and wide potentially causing global pandemics, as was the case with COVID-19, if not caught in time. It is not feasible to produce a new vaccine and a new set of antibody drugs to combat every possible virus. Even if vaccines and antibodies are produced, the virus would escape by generating variants, as the world has witnessed during the COVID-19 pandemic.

The US Government is active in ensuring that suspected or confirmed ebolavirus cases do not

15 Substantial work was also performed to develop small chemical potentially broad-spectrum agents. Remdesivir was the only small chemical that entered the PALM clinical trials ca. 2018-2019 but failed to show effectiveness. Small chemicals are readily escaped by viruses often with just single mutations.

enter the general population in the USA. To this end, travel from DRC has been restricted, with pre-travel quarantine requirements imposed, and suspect travelers are directed to screening at specific airports and may be further quarantined.

Travelers going to and from Central Africa need to constantly check travel restrictions as well as travel limitations in light of these changing outbreak conditions.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these

forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact: NanoViricides, Inc.
[email protected]
Public Relations Contact: [email protected]
Source: NanoViricides, Inc.

30-Year Treasury Yields Just Hit Their Highest Level Since 2007. Four Forces Are Colliding at Once.

Posted on August 18, 2026August 18, 2026 by [email protected]

The 30-year US Treasury yield climbed to 5.327% on Tuesday, its highest level in 19 years, as stalled talks to end the US-Iran war and renewed fears of escalation pushed oil prices above $90 a barrel and reignited inflation concerns across global markets. The benchmark 10-year yield rose to 4.739%. The selloff was not contained to US markets either, spreading to Japan, where the 10-year government bond yield hit a 30-year peak, and to Europe, where Germany’s 10-year Bund yield touched its highest level since 2011 and France’s 10-year yield reached a 17-year high.

The proximate trigger is the same conflict that has driven energy markets and inflation expectations for much of the year. Iran told officials it would shift to a fully offensive military posture after negotiations toward a permanent end to the war stalled, while Washington has ruled out extending the ceasefire agreement reached in June. With the Strait of Hormuz still effectively shut, the best-case scenario according to strategists covering the region is a prolonged standoff that continues restricting crude flows, while the worst case is a resumption of active fighting.

This Is Not Just an Oil Story

What makes this move genuinely notable is that oil and geopolitics are only part of the explanation. Analysts covering global rates point to at least three additional structural forces pushing long-term yields higher independent of the Iran conflict. The surge in borrowing from AI hyperscalers, whose capital expenditure plans have accelerated sharply throughout 2026, is forcing bond buyers to demand higher returns to absorb the flood of new debt hitting markets. A rising US budget deficit is compounding that pressure, with recent Treasury auctions drawing unusual attention, a 10-year note auction clearing at 4.683%, its highest yield in 19 years, and a 30-year bond auction stopping at 5.216%, a 25-year peak.

Notably, one strategist covering the move specifically named Federal Reserve Chair Kevin Warsh’s shift toward a more opaque communication style as a contributing factor to rising yields, a shift in tone that has drawn scrutiny ahead of his upcoming Jackson Hole address and the market confusion that followed his July press conference. Reduced clarity from the Fed appears to be compounding, rather than easing, the uncertainty already priced into long-duration debt.

For companies operating below the $2 billion market cap threshold, this combination of forces is directly consequential. Small and microcap companies carry disproportionately more variable-rate debt than large cap peers, and a 30-year yield at its highest level since 2007 signals that the higher-cost-of-capital environment weighing on smaller businesses is not easing, it is intensifying. One market strategist noted that for much of the past 15 years, investors operated in a market where stable-to-falling rates consistently supported higher stock prices, but recent Treasury auctions suggest that landscape is genuinely shifting, with investors increasingly focused on the growing scale of US debt and questions about fiscal discipline. For small cap investors, that shift deserves close attention heading into the fall.

Xerox Holdings Corporation (XRX) – Reinvention Creates a Path to Sustainable Earnings Growth

Posted on August 18, 2026August 18, 2026 by [email protected]

Tuesday, August 18, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with an Outperform rating and a $5 price target. Our constructive view reflects the company’s multiyear transformation through the Lexmark acquisition, expansion of IT Solutions and Digital Services, and continued focus on operating efficiency. We believe these initiatives can moderate revenue declines, improve profitability and cash generation, and ultimately support a multiyear earnings recovery and valuation re-rating.

Lexmark Integration Positioned to Drive Significant Profit Growth. The acquisition of Lexmark expands Xerox’s global scale and is expected to generate at least $350 million in gross cost synergies by the end of 2027. In our view, it provides a clear path toward ameaningful improvement in operating leverage and competitive positioning.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

QuoteMedia Inc. (QMCI) – Double-Digit Revenue Growth, Improving Margins Signal Operating Leverage

Posted on August 18, 2026August 18, 2026 by [email protected]

Tuesday, August 18, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q2 revenue growth. QuoteMedia reported Q2 revenue of $5.45 million, up 11% YoY from $4.93 million, although below our $5.63 million estimate. The quarter marked the company’s second consecutive quarter of double-digit revenue growth, supported by new client wins and expansion within existing enterprise relationships.

Improving profitability. Gross margin increased to 50% from 46% in the year-earlier period, while adj. EBITDA increased to $241,000 from $99,000. The net loss narrowed substantially to $362,000 from $854,000. We believe the improving results provide early evidence of the operating leverage inherent in the company’s business model.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Everyone Sees the Small Cap Rally. Almost No One Is Buying It

Posted on August 18, 2026August 18, 2026 by [email protected]

Small-cap stocks just delivered their best first half on record, and almost nobody is talking about where the money went next.

U.S. small caps returned 22.93% in the first half of 2026, outpacing large caps at 9.55% by the widest margin in history for that stretch. It is the kind of number that normally sends investors scrambling to add exposure. Yet the flow of capital into small-cap funds tells a different story, one that raises an obvious question: if small caps are winning this decisively, why hasn’t the money followed?

The data shows a real disconnect. Small-cap ETFs pulled in roughly $7 billion during the first half of the year. Large-cap ETFs, by comparison, absorbed $309 billion over the same period. On the mutual fund side, small-cap funds have seen about $8 billion in net inflows year to date, a modest turnaround after $8 billion in outflows the year before. Actively managed small-cap funds have fared even worse, continuing to lose assets as investors keep shifting toward passive strategies more broadly.

In other words, small caps are outperforming while investors remain largely on the sidelines. That gap between performance and participation is unusual, and some market strategists see it as meaningful. State Street has pointed to the lag as a sign the rally may have room to keep running, arguing that a rotation this significant with so little capital chasing it is not the profile of a crowded trade. If allocators eventually catch up to the performance numbers, the argument goes, the current move could extend further rather than reverse.

Not everyone is convinced. BlackRock has reportedly kept a more cautious stance on small caps as a group, citing ongoing uncertainty around financing conditions and the broader macro backdrop. Smaller companies tend to carry more floating-rate debt and less balance sheet cushion than their large-cap counterparts, which makes them more sensitive to shifts in interest rates and credit availability. That sensitivity cuts both ways. It can amplify gains when conditions turn favorable, but it can just as easily amplify losses if the environment shifts.

There is also a more speculative data point worth noting with some caution. MoneyFlows, a firm that tracks proprietary money-flow signals, claims that nearly 98% of its tracked equity inflows this year have gone into companies with market capitalizations under $300 billion, which it frames as evidence of institutional accumulation building beneath the surface. Unlike the ETF and mutual fund flow data from sources such as Morningstar and State Street, this is a promotional research product, and the claim should be weighed accordingly.

What is clear is that small caps have already made their move on performance. Whether capital flows catch up, stall, or reverse from here may say more about the durability of this rally than the first-half numbers themselves. For investors watching the space, the next few months of fund flow data could matter as much as the earnings results that got small caps here in the first place.

Fulcrum Therapeutics Is Becoming a Migraine Drug Company. Here Is How

Posted on August 17, 2026August 17, 2026 by [email protected]

Fulcrum Therapeutics (Nasdaq: FULC) announced Monday it has entered into a definitive agreement to merge with privately held Slate Medicines in an all-stock transaction. The combined company will operate under the Slate Medicines name and pivot entirely away from Fulcrum’s original rare hematological disease pipeline toward Slate’s portfolio of next-generation migraine therapeutics. Alongside the merger, the companies announced an oversubscribed $245 million private placement from a syndicate of healthcare investors, expected to fund the combined operations into 2029.

This deal follows one of the more difficult stretches in Fulcrum’s history, and understanding that context is essential to understanding why this transaction exists at all. In June, Fulcrum discontinued development of pociredir, its lead drug candidate for sickle cell disease, after the FDA raised concerns about the drug’s benefit-risk profile in a recent meeting. Regulators specifically flagged an unexpectedly high rate of secondary hematologic malignancies observed in patients treated with a chemically related PRC2 inhibitor from another company, a drug that its own manufacturer had voluntarily pulled from shelves worldwide earlier this year. Fulcrum’s stock fell more than 50% on the news, and the company subsequently laid off 48 of its 57 employees, roughly 85% of its workforce, while beginning a formal review of strategic alternatives that included a merger, business combination, or other transaction. As of March 31, Fulcrum held $333.3 million in cash and marketable securities, enough runway to keep the company operating into 2029 on its own. Separately, and worth noting for full transparency, a law firm publicly announced last week it is investigating potential securities law violations tied to Fulcrum’s disclosures around the pociredir discontinuation. That investigation is ongoing and its outcome, if any, is not yet known.

Slate’s lead candidate, SLTE-1009, is a clinical-stage subcutaneous monoclonal antibody targeting PACAP and VIP pathways, developed as a potentially best-in-class preventative treatment for migraine. Migraine remains a large and underserved therapeutic market, and antibody-based preventative treatments targeting neuropeptide pathways have become one of the more actively pursued mechanisms in the space over the past several years.

A Familiar Small Cap Biotech Pattern

This transaction follows a structure we have covered before on ChannelChek: a publicly traded biotech whose original clinical program failed, leaving it with a Nasdaq listing, meaningful cash reserves, and no viable path forward on its own, becomes the vehicle through which a well-funded private biotech gains public market access without pursuing a traditional IPO. Rather than navigating the lengthy IPO process independently, Slate secures a public listing, a syndicate of institutional capital, and immediate resources to advance its lead asset, all in a single coordinated transaction.

For investors tracking this space, the Fulcrum-Slate combination is a useful reminder that a failed clinical trial does not automatically end a company’s story, particularly when meaningful cash remains on the balance sheet. It also underscores a genuine risk worth weighing carefully: shareholders who bought into Fulcrum’s original rare disease thesis are now effectively invested in an entirely different company, pursuing an unrelated therapeutic area, following a transaction that arrives while questions about the prior program’s disclosures remain unresolved. Reverse mergers of this type can create real value when the incoming asset is genuinely differentiated, but investors should evaluate the new company on its own clinical and commercial merits rather than assuming continuity with the business they originally invested in.

Release – Resolution Secures White House FAST-41 Transparency Coverage for Golden Gate Tungsten-Gold Target

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on RLMLF

July 17, 2026

PERMITTING COUNCIL SUPPORT EXPECTED TO ACCELERATE AGGRESSIVE EXPLORATION AND DEVELOPMENT PROGRAM ACROSS ENTIRE GOLDEN GATE TARGET AS RESOLUTION CONTINUES TO DEVELOP ITS INTEGRATED IDAHO ANTIMONY-TUNGSTEN-GOLD CRITICAL METALS PLATFORM

July 17, 2026 (Source) — HIGHLIGHTS

This is the second FAST-41 status granted to Resolution Minerals, demonstrating the high calibre of the Golden Gate asset and its strategic value as a potential source of U.S. domestic tungsten supply, and highlights the level of engagement RML has with the U.S. Government and the Permitting Council, and the attention Resolution’s projects are receiving from the highest levels of the current Administration.
FAST-41 is a special permitting framework being utilised by the Trump Administration to accelerate permitting and the development of critical U.S. infrastructure projects and to provide solutions for U.S. national security.
RML’s Golden Gate Project was added to the FAST-41 Transparency Dashboard in response to President Trump’s Executive Order on Immediate Measures to Increase American Mineral Production¹, to reduce reliance on foreign adversaries for the supply of critical minerals, especially during times of war.
RML has been working closely with key Federal agencies and Administration leadership, including the Permitting Council, which has reviewed RML’s U.S. assets and has recognised their strategic importance to addressing the United States’ critical metals supply deficit and lack of domestic production.
With RML’s Antimony Ridge Project receiving FAST-41 Transparency status in April 2026, both of the Company’s primary development targets at the Horse Heaven Project, Antimony Ridge and Golden Gate, have been prioritised by the U.S. Government for streamlined permitting.
The Golden Gate and Antimony Ridge targets are within RML’s 15,000-acre Horse Heaven Tungsten-Antimony-Gold Project located in Idaho, USA, directly adjacent to Perpetua Resources’ recently permitted ~A$3.5 billion Stibnite Gold Project.
A Plan of Operations for Golden Gate has been submitted to, and accepted by, the US Forest Service for an exploration and development program that will include construction of new roads between Golden Gate North and Golden Gate South and allow up to 340 drill holes and 2,000 feet of trenching.
The Golden Gate Project includes the past-producing Golden Gate Tungsten Mine, which operated intermittently between the period from approximately 1952 to 1980, with reported tungsten production grades ranging between 1.5% and 2.0%.
The combination of Golden Gate and Antimony Ridge positions Resolution to pursue an integrated critical metals development pathway spanning exploration, metallurgy, and potential downstream processing in a tier-one U.S. jurisdiction.
FAST-41 status is expected to fast-track permitting, enhance investor visibility and support engagement with potential strategic partners and funding sources aligned with the U.S. critical minerals policy.
FAST-41 status bodes extremely well for the Company’s upcoming NASDAQ listing.

Resolution Minerals Ltd (ASX: RML; OTCQB: RLMLF) (“Resolution” or the “Company”) is pleased to announce that its Golden Gate Project in Idaho, USA has been selected for inclusion in the U.S. Federal FAST-41 Permitting Transparency Program.

FAST-41 designation is expected to accelerate permitting timelines through enhanced inter-agency coordination, transparent milestone tracking and dedicated federal oversight. The Program provides Resolution with a clear pathway to advance its proposed bulk sampling and drilling activities at Antimony Ridge, a high-grade, past producing antimony project, located within the Company’s 100% owned Horse Heaven Project.

Importantly, FAST-41 selection supports Resolution’s broader strategy to develop a U.S.-focused critical mineral platform. Golden Gate is one of several advancing components within Horse Heaven Project, which also includes:

A recently acquired processing mill and infrastructure known as the Johnson Creek Tungsten Mill.
Historical tungsten stockpiles located adjacent to the Golden Gate Tungsten Mine portal and at the Johnson Creek Mill with potential near-term development optionality.
A fully funded, ongoing Phase 2 drilling program at Golden Gate, comprising up to 45 holes targeting resource definition.

Together, these assets position Resolution to pursue an integrated development pathway spanning exploration, metallurgy and potential downstream processing of antimony, tungsten, and gold in a tier-one U.S. jurisdiction.

Golden Gate is located immediately adjacent to Perpetua Resources’ Stibnite Gold Project, highlighting the region’s growing importance as a strategic hub for U.S. critical minerals. With the United States seeking to secure domestic supply of key metals such as antimony, Resolution is well placed to contribute to supply chain resilience while advancing multiple near-term development catalysts.

The inclusion of Golden Gate in the FAST-41 program follows closely on the designation of RML’s Antimony Ridge Project as a FAST-41 project. It is the intention of the US Forest Service to permit both the Antimony Ridge Plan of Operation and the Golden Gate Plan of Operation under one NEPA process, helping to streamline ongoing permitting at both projects.

Craig Lindsay, Resolution’s CEO – US Operations, commented:

“We are very pleased that Golden Gate has been selected for FAST-41 Transparency Coverage. We now have two separate development targets within the Horse Heaven Project under the FAST-41 program. Interestingly, I am not aware of any other critical metals company with two FAST-41 projects, which I believe is a mark of the potential importance of Horse Heaven in the US achieving its goal of developing domestic supplies of both antimony and tungsten.

Golden Gate represents a key piece of Resolution’s broader strategy to develop a U.S.-based critical minerals platform. With exploration, processing infrastructure and multiple development pathways now coming together at Horse Heaven, we believe the Company is uniquely positioned to capitalise on strong demand for antimony, tungsten and gold.”

FAST-41 Projects and the Permitting Council

The Washington, DC-based Permitting Council was established by Congress in 2015 under Title 41 of the Fixing America’s Surface Transportation Act (FAST-41) to improve the efficiency, transparency and accountability of the federal permitting process.

The Council coordinates environmental reviews and authorisations across multiple federal agencies, acting as a central project manager across for qualifying projects. FAST-41 projects benefit from structured inter-agency coordination, defined permitting timelines and public tracking via the Federal Permitting Dashboard.

The Permitting Council is comprised of the Executive Director (Chair), and 15 other members, including the Deputy Secretary (or equivalent) from 13 Federal agencies, the Chair of the Council on Environmental Quality (CEQ), and the Director of the Office of Management and Budget (OMB). The Office of the Executive Director (OED) executes on the actions of the Council, and Permitting Council statutory authorities, programs, and initiatives. The Office of the Executive Director coordinates federal environmental reviews and authorisations for projects that qualify for FAST-41 coverage, which are in turn entitled to public permitting timetables and transparent, collaborative management of those timetables on the Federal Permitting Dashboard.

More information on the Permitting Council and FAST-41 can be found at www.permitting.gov.

Next Steps

Resolution will work closely with its primary permitting authority, the US. Forest Service, to advance the Golden Gate Plan of Operations through the FAST-41 process.

Following approval, the Company intends to commence a significant drill campaign intended to both increase the drill coverage of the Golden Gate North and Golden Gate South targets and confirm whether the gold and tungsten mineralization is linked geologically (the area between North and South have never been drilled, but RML has developed a geologic model that suggests the potential for both targets to be one large contiguous body of mineralisation).

On a parallel basis, RML is continuing to implement its ongoing 13,700 metre (45,000 foot) drill program at Golden Gate, with 22 holes currently completed and initial results for the first several holes expected by the end of July.

Authorised for release by the Board of Resolution Minerals Ltd.

For further information, please contact:

Ari Zaetz
Executive Director
Resolution Minerals Ltd
M: +61 493 254 526
[email protected]

Jane Morgan
Investor Relations
Jane Morgan Management
M: +61 405 555 618
[email protected]

Forward Looking Statements

This announcement may contain forward-looking statements. These statements relate to the Company’s expectations, beliefs, intentions or strategies regarding the future. These statements can be identified by the use of words like “anticipate”, “believe”, “intend”, “estimate”, “expect”, “may”, “plan”, “project”, “will”, “should”, “seek” and similar words or expressions containing same. These forward-looking statements reflect the Company’s views and assumptions with respect to future events as of the date of this release and are subject to a variety of unpredictable risks, uncertainties, and other unknowns. Actual and future results and trends could differ materially from those set forth in such statements due to various factors, many of which are beyond our ability to control or predict. These include, but are not limited to, risks or uncertainties associated with the acquisition and divestment of projects, joint venture and other contractual risks, metal prices, exploration, development and operating risks, competition, production risks, sovereign risks, regulatory risks including environmental regulation and liability and potential title disputes, availability and terms of capital and general economic and business conditions.

Given these uncertainties, no one should place undue reliance on any forward-looking statements attributable to the Company, or any of its affiliates or persons acting on its behalf. Subject to any continuing obligations under applicable law, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in this announcement to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any such statement is based.

References:

https://www.whitehouse.gov/presidential-actions/2025/03/immediate-measures-to-increase-american-mineral-production

https://www.mining.com/tungsten-crunch-can-be-fixed-before-prices-spike-further-bmo

https://www.nationalacademies.org/read/12028/chapter/10

D. W. Kalmbach et al 2021: NI 43-101 TECHNICAL REPORT ON THE HORSE HEAVEN GOLD PROJECT VALLEY COUNTY

Release – Townsquare Announces Strategic Digital Advertising Partnership with Midlands Media Group

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on TSQ

Released : 08/17/2026

PURCHASE, N.Y., Aug. 17, 2026 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare” or the “Company”), a leader in digital advertising and marketing solutions focused on markets outside of the Top 50 in the United States, announced today a strategic digital advertising partnership with Midlands Media Group, a Columbia, S.C.-based multimedia company with two radio stations, a digital news service, a digital ticketing provider, a discount certificate site, and a comprehensive digital advertising platform.

“Midlands Media Group has built a highly local portfolio of radio and digital news brands with engaged audiences and a strong market presence, making them an ideal partner for our digital platform and services,” said Shaun Collignon, CRO of Townsquare Ignite, the Company’s Digital Advertising division. “By combining their multi-channel reach with our proprietary technology, data-driven strategy, and execution expertise, we are well positioned to unlock new revenue opportunities and drive meaningful, measurable growth.”

In 2024, Townsquare launched its Media Partnerships division as part of Townsquare Ignite, its Digital Advertising segment, to bring its industry-leading digital solutions to other local media companies. The division provides a white-label service that allows partners to tap into the same data-driven strategies and proprietary technology that have powered Townsquare’s success, with digital now contributing more than half of the Company’s total revenue and profit.

This partnership with Midlands Media Group is one of 16 strategic alliances Townsquare has established under this initiative, collectively expanding the Company’s reach into 41 new markets beyond its owned and operated footprint, including those in the Top 50 markets. Townsquare will work closely with Midlands Media Group, which operates in the #90-ranked MSA in the United States, to deliver customized, data-driven advertising solutions tailored to local, regional, and national clients, helping to grow their digital business while enhancing the value of their trusted broadcast and multimedia platforms.

“This alliance reflects our continued commitment to helping leading local media companies to more fully monetize their audiences across platforms and deliver stronger results for their clients,” Collignon added.

“Midlands Media Group is very excited to partner with Townsquare Ignite to further expand our digital solutions capabilities. After extensive evaluation and industry experience, we believe Townsquare Ignite is best-in-class and fully committed to digital growth. Their team and technology position us to accelerate results for our clients across all platforms,” said Keith Stover, President & CEO of Midlands Media Group.

Marie Stover, Chief Operating Officer of Midlands Media Group, added: “Our unique focus is to super-serve the marketing needs of local businesses in our community. Adding Townsquare Ignite’s digital marketing component to our market-leading radio and news products positions us to deliver fully integrated campaigns that are authentic, high-impact, and measurable. We look forward to what this partnership will bring to our clients and communities.”

About Townsquare Media, Inc.
Townsquare is a community-focused digital and broadcast media and digital marketing solutions company principally focused outside the top 50 markets in the U.S. Townsquare Ignite, our robust digital advertising division, specializes in helping businesses of all sizes connect with their target audience through data-driven, results based strategies, by utilizing a) our proprietary digital programmatic advertising technology stack with an in-house demand and data management platform and b) our owned and operated portfolio of more than 400 local news and entertainment websites and mobile apps along with a network of leading national music and entertainment brands, collecting valuable first party data. Townsquare Interactive, our subscription digital marketing services business, partners with SMBs to help manage their digital presence by providing a SAAS business management platform, website design, creation and hosting, search engine optimization and other digital services. And through our portfolio of local radio stations strategically situated outside the Top 50 markets in the United States, we provide effective advertising solutions for our clients and relevant local content for our audiences. For more information, please visit www.townsquaremedia.com, www.townsquareinteractive.com, and www.townsquareignite.com.

About Midlands Media Group
Midlands Media Group is a Columbia, S.C.-based multimedia company and the only locally owned and operated media company in the Columbia market. The company connects local audiences and businesses through two radio stations, a digital news service, a digital ticketing provider, a discount certificate platform and a comprehensive suite of digital advertising solutions.

Townsquare Contact
Claire Yenicay
(203) 900-5555
[email protected]

Midlands Media Group Contact
Keith Stover
803-753-6802
[email protected]

Source: Townsquare Media Inc.

Release – Kuya Silver Reports Q2, 2026 Financial Results – Advances Bethania Mine Development and Drilling Program

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on KUYAF

Kuya Silver to hold a conference call webinar on August 17, 2026 to discuss Q2 2026 financial results

Toronto, Ontario–(Newsfile Corp. – August 17, 2026) – Kuya Silver Corporation (CSE: KUYA) (OTCQB: KUYAF) (FSE: 6MR1) (the “Company” or “Kuya Silver”) is pleased to announce financial and operating results for the six months ending June 30, 2026.

The Company maintained a strong cash position of $25.5 million as at June 30, 2026, providing a solid financial foundation to support its exploration program, mine development initiatives including the construction of the new ramp required to support Bethania’s Phase 1 ramp-up to 350 tonnes per day.

The Company’s revenue increased significantly to $2.7 million during the first six months ended June 30, 2026, compared to $1.3 million in the comparable period of 2025, reflecting increased silver production from the Bethania operation in addition to the positive effect higher silver prices. Revenue for the quarter was $1.25 million.

Exploration and evaluation expenditures were $1.0 million during the first six months of 2026, compared to $1.3 million in the comparable period of 2025. Expenditures at Bethania remained broadly consistent year over year, while expenditures at Silver Kings decreased as the Company continues to evaluate low-cost opportunities to unlock the project’s potential. Exploration and evaluation expenditures are expected to increase during the second half of 2026 as the expanded drilling program commences and Bethania advances critical infrastructure development and ramp-up activities.

The Company recorded a net loss of $2.8 million for the six months ended June 30, 2026, compared to $1.35 million in the same period of 2025. The larger net loss primarily reflects expenses related to significantly greater activity levels at Bethania associated with the ramp-up, together with increased administrative expenses as the Company continues to build the organizational structure and capabilities required to support its growing operations. The increase was partially offset by higher revenue from Bethania and lower exploration and evaluation expenditures.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5945/309739_7a052289f4a5baa2_001full.jpg

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/5945/309739_7a052289f4a5baa2_002full.jpg

Camila Plant Acquisition Update

The Company continues to the Company continues to evaluate the proposed acquisition and expects to provide a further update in due course.

Outlook

Kuya Silver continues the process to onboard contractors at the Bethania mine to augment its workforce, which is expected to accelerate both mine development and underground drilling productivity in Q3 2026, continuing for the remainder of the year and into 2027. In the near term, the mine team has initiated a focused development program, allocating additional resources to unlock mineralized material for mining later this year and into 2027.

Upcoming Conference Call Webinar

Kuya Silver will host a conference call webinar taking place on Monday, August 17th at 9:00 am ET / 6:00 am PT. During the event, Kuya management will provide an in-depth overview of Q2 2026 financial results, cover recent news on the Silver Kings project and provide a market update on operations at the Bethania Project. A live Q&A will follow the presentation.

A replay of the webinar will be made available later that day through the same link.

National Instrument 43-101 Disclosure

The technical content of this news release has been reviewed and approved by Osbaldo Zamora, PhD., P.Geo., Vice President Exploration with Kuya Silver, Qualified Persons as defined by National Instrument 43-101.

About Kuya Silver Corporation

Kuya Silver is a Canadian‐based, growth-oriented mining company with a focus on silver. Kuya Silver operates the Bethania silver mine in Peru, while developing district-scale silver projects in mining-friendly jurisdictions including Peru and Canada.

For further information, please contact:

David Stein, President & Chief Executive Officer
Telephone: (604) 398-4493
Email: [email protected]
Website: www.kuyasilver.com

Reader Advisory

This news release contains statements that constitute “forward-looking information,” including statements regarding the plans, intentions, beliefs, and current expectations of the Company, its directors, or its officers with respect to the future business activities of the Company. The words “may,” “would,” “could,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect,” “must,” “next,” “propose,” “new,” “potential,” “prospective,” “target,” “future,” “verge,” “favorable,” “implications,” and “ongoing,” and similar expressions, as they relate to the Company or its management, are intended to identify such forward-looking information. Investors are cautioned that statements including forward-looking information are not guarantees of future business activities and involve risks and uncertainties, and that the Company’s future business activities may differ materially from those described in the forward-looking information as a result of various factors, including but not limited to fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing, and general economic, market, and business conditions. There can be no assurances that such forward-looking information will prove accurate, and therefore, readers are advised to rely on their own evaluation of the risks and uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the Canadian Securities Exchange nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/309739

Release – Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on COCP

August 17, 2026

Download as PDF

BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.

“Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide,” said Roger Kornberg, Ph.D., Chairman of the Board, Chief Scientist, and Chairman of Scientific Advisory Board at Cocrystal and Nobel laureate. “Her clinical and scientific insights will be invaluable as we work to advance the clinical development of CDI-988 for norovirus, as well as the broader development of our antiviral pipeline.”

James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, “I’ve had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn’t be more pleased to have her insight guiding Cocrystal at this pivotal stage.”

Dr. Brosgart has extensive experience in government service and biopharmaceutical consulting, has served on the boards of numerous biotechnology companies, and was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She is a member of the Board of Directors of the Hepatitis B Foundation, previously co-chaired the National Task Force on Hepatitis B and was a Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and the Viral Hepatitis Action Coalition at the CDC Foundation. She currently sits on the Boards of Directors of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, and previously held board positions at Abivax, Mirum Pharmaceuticals, Tobira Therapeutics and Juvaris. Dr. Brosgart spent more than a decade at Gilead Sciences as well, where she played a critical role in the development and regulatory approval of the antiviral therapies Viread^® and Hepsera^®. She received her M.D. from the University of California, San Francisco (UCSF) School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.

About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For more information, visit www.cocrystalpharma.com.

Investor Contact:
Nic Johnson
Russo Partners
[email protected]
(303) 482-6405

Media Contact:
David Schull
Russo Partners
[email protected]
(858) 717-2310

Source: Cocrystal Pharma, Inc.

Released August 17, 2026

Release – V2X Congratulates Chief Growth Officer Roger Mason on Confirmation as Director of the National Reconnaissance Office

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on VVX

August 17, 2026

Download(opens in new window)

RESTON, Va., Aug. 17, 2026 /PRNewswire/ — V2X, Inc. (NYSE: VVX), a leading provider of global mission solutions supporting defense, national security and civilian customers, congratulates Chief Growth Officer Dr. L. Roger Mason Jr. on his confirmation by the U.S. Senate to serve as Director of the National Reconnaissance Office.

Since joining V2X in 2025, Mason has led the company’s integrated growth organization, overseeing corporate strategy, business development, technology development, marketing and communications, government affairs, competitive intelligence, and growth operations. Under his leadership, V2X strengthened its strategic positioning across key national security priorities and advanced opportunities supporting the evolving needs of defense and intelligence customers.

“Roger has been an exceptional leader, trusted colleague and advocate for our customers and employees,” said Jeremy C. Wensinger, President and Chief Executive Officer of V2X. “His strategic vision, integrity and commitment to the national security mission have left a lasting impact on our company. While we will certainly miss his leadership, we are incredibly proud to see him continue his distinguished career in public service. On behalf of the entire V2X team, we congratulate Roger and wish him every success as he leads one of our nation’s most important intelligence organizations.”

V2X will announce plans regarding the Chief Growth Officer role at a later date.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,000 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
[email protected]
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
[email protected]
571-338-5195

View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-congratulates-chief-growth-officer-roger-mason-on-confirmation-as-director-of-the-national-reconnaissance-office-302852419.html

SOURCE V2X, Inc.

Release – Kratos and GE Aerospace’s GEK800 Engine Receives U.S. Military Type Designation F143-ZZ-100 and EMD Contract Award for JASSM

Posted on August 17, 2026August 17, 2026 by [email protected]

Research News and Market Data on KTOS

August 17, 2026

PDF VersionEngine selected as a second-source propulsion system for the Joint Air-to-Surface Standoff Missile (JASSM), advancing the program to deliver small, low-cost, high-performance engines for missiles and uncrewed platforms

SAN DIEGO, Aug. 17, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, and GE Aerospace (NYSE: GE) today announced that the GEK800 engine, which received the U.S. Military Engine Type Designation F143-ZZ-100, has been awarded a contract with the United States Air Force for the Engineering, Manufacturing and Development (EMD) of the turbofan as a second-source propulsion system for the Joint Air-to-Surface Standoff Missile (JASSM).

The designation and contract mark advancement of the program designed to provide small, low-cost, high-performance engines for use in cruise missiles, collaborative combat-type aircraft, and other uncrewed aerial vehicles.

“The F143-ZZ-100 designation and EMD award are a testament to the strong performance and capability of the GEK800 engine and the strength of our partnership with Kratos. This reflects years of disciplined engineering to deliver propulsion systems that meet the evolving, mission-critical requirements of our military customers,” said Amy Gowder, President and CEO of GE Aerospace Defense & Systems.

“Kratos has been working with our outstanding partner GE Aerospace and the United States Air Force to support the Department of War in reindustrializing U.S. manufacturing capacity and capability in the area of low cost, rapidly manufacturable, in large quantities, jet engines for drones, cruise missiles and other systems. Kratos and GE Aerospace are making significant investments with our government partners, to support U.S. National Security priorities,” said Eric DeMarco, President and CEO of Kratos.

The GEK800, now designated the F143, is an 800-lb thrust turbofan engine designed to power long-range missiles and other uncrewed applications. With a combination of internal investment plus support and funding from the Air Force Research Laboratory (AFRL), Kratos and GE Aerospace began working together in 2023 to complete a Technology Maturation and Risk Reduction (TMRR) phase including testing of the engine. The joint team has completed more than 50 engine starts in ground testing at Kratos and GE Aerospace testing facilities, and in 2025 successfully completed altitude testing at Purdue University’s Maurice J. Zucrow Laboratories.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading-edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value-add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for C2 and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com and follow Kratos on LinkedIn and X.

About GE Aerospace
GE Aerospace is a global aerospace propulsion, services, and systems leader with an installed base of approximately 49,000 commercial and 29,000 military aircraft engines. With a global team of approximately 53,000 employees building on more than a century of innovation and learning, GE Aerospace is committed to inventing the future of flight, lifting people up, and bringing them home safely. Learn more about how GE Aerospace and its partners are defining flight for today, tomorrow, and the future at www.geaerospace.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 28, 2025, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Kratos Press Contact:
Claire Cantrell
[email protected]

Kratos Investor Information:
877-934-4687
[email protected]

GE Aerospace Press Contact:
Deb Case
[email protected]

Xcel Brands (XELB) – Commercialization Advances: Building Toward a Second-Half Revenue Inflection

Posted on August 17, 2026August 17, 2026 by [email protected]

Monday, August 17, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

George Proost, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results were softer than expected, largely due to timing. Revenue was approximately $1.1 million, compared with $1.3 million in the prior-year period, reflecting the Judith Ripka divestiture and delays associated with QVC’s bankruptcy and vendor-credit issues. Importantly, the QVC-related disruptions appear to have largely been resolved.

Commercialization remains the key story as the creator portfolio moves into the market. With the portfolio’s social media reach having expanded from roughly 5 million to more than 46 million followers, we believe the company has assembled a compelling audience from which to build consumer brands. The next several quarters should provide evidence regarding Xcel’s ability to convert that audience into sustainable royalty revenue.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).